XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Accrued Liabilities
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Accrued Liabilities of -$3.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$1.51M, a 128.26% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.50M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $3.70M, a 12.91% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $2.83M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $3.31M, a 9.42% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $3.65M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$5.86M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was -$11.38M, a 190.67% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.01M 10-Q · filed 2026-08-06 | $695.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.50M 10-Q · filed 2026-05-07 | $2.21M derived: sum of 2 quarters · filed 2026-05-07 | $5.04M derived: sum of 3 quarters · filed 2026-05-07 | $10.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.54M derived: sum of 2 quarters · filed 2026-03-02 | $11.89M derived: sum of 3 quarters · filed 2026-08-06 | $3.31M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.18M derived: sum of 2 quarters · filed 2026-08-06 | -$398.00K 10-Q · filed 2025-11-06 | $3.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.23M 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | -$22.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$8.58M 10-Q · filed 2026-05-07 | -$4.33M derived: sum of 2 quarters · filed 2026-05-07 | -$5.37M derived: sum of 3 quarters · filed 2026-05-07 | -$3.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.21M derived: sum of 2 quarters · filed 2026-03-02 | $4.77M derived: sum of 3 quarters · filed 2026-03-02 | $3.65M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $520.00K derived: sum of 2 quarters · filed 2025-11-06 | -$603.00K 10-Q · filed 2025-11-06 | $5.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $442.00K 10-Q · filed 2025-08-07 | $6.59M derived: sum of 3 quarters · filed 2026-03-02 | $5.79M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$1.12M 10-Q · filed 2025-05-08 | $5.03M derived: sum of 2 quarters · filed 2026-03-02 | $4.23M derived: sum of 3 quarters · filed 2026-03-02 | $6.95M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.35M derived: sum of 2 quarters · filed 2026-03-02 | $8.08M derived: sum of 3 quarters · filed 2026-03-02 | -$5.86M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$799.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.93M derived: sum of 2 quarters · filed 2024-11-08 | -$12.01M 10-Q · filed 2024-11-08 | -$11.25M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$11.21M 10-Q · filed 2024-08-08 | -$10.46M derived: sum of 3 quarters · filed 2025-03-06 | -$10.11M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$13.93M 10-Q · filed 2024-05-09 | -$13.18M derived: sum of 2 quarters · filed 2025-03-06 | -$12.84M derived: sum of 3 quarters · filed 2025-03-06 | -$11.66M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $751.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.09M derived: sum of 2 quarters · filed 2025-03-06 | $2.27M derived: sum of 3 quarters · filed 2025-03-06 | -$11.38M 10-K · filed 2025-03-06 |
| 2022-09-30 | $343.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.52M derived: sum of 2 quarters · filed 2023-11-09 | -$12.13M 10-Q · filed 2023-11-09 | -$4.23M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$12.48M 10-Q · filed 2023-08-08 | -$4.57M derived: sum of 3 quarters · filed 2024-03-06 | -$504.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$13.66M 10-Q · filed 2023-05-09 | -$5.75M derived: sum of 2 quarters · filed 2024-03-06 | -$1.68M derived: sum of 3 quarters · filed 2024-03-06 | $1.69M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $11.97M derived: sum of 2 quarters · filed 2024-03-06 | $15.35M derived: sum of 3 quarters · filed 2024-03-06 | $12.56M 10-K · filed 2024-03-06 |
| 2021-09-30 | $4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $7.44M derived: sum of 2 quarters · filed 2022-11-09 | $4.65M 10-Q · filed 2022-11-09 | $8.93M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $582.00K 10-Q · filed 2022-08-10 | $4.86M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$2.79M 10-Q · filed 2022-05-11 | $1.49M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$2.21M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$6.49M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |